3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Recurrence
1
Neoplasm Metastasis
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
B-Cell Malignancies
1
Interventions
Dexamethasone
33
Cyclophosphamide
31
fludarabine
19
venetoclax
18
Lenalidomide
16
Bortezomib
16
Cytarabine
13
pembrolizumab
12
Calcium Dobesilate
12
Carboplatin
11
fludarabine phosphate
10
Rituximab
10
pomalidomide
9
Gemcitabine
9
Nivolumab
8
Azacitidine
7
daratumumab
6
carfilzomib
6
blinatumomab
6
Decitabine
6
Bendamustine Hydrochloride
6
selinexor
5
obinutuzumab
5
ibrutinib
5
Vincristine
5
Temozolomide
5
Methotrexate
5
Etoposide
5
Cisplatin
5
tafasitamab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recurrence
×
parsaclisib
×
Clear all
NCT04809467
2026-02-04
topMIND
Incyte Corporation
Phase 1/2
Terminated
54 enrolled
23 charts